Direct Biologics, LLC   Report issue

For profit Phase 2 Phase 3
Founded: Austin TX United States (2019)

Organization Overview

First Clinical Trial
2020
NCT04493242
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Direct Biologics, LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

exoflo (3 trials)

Drugs in Phase 2 Trials (2)

db-001 (1 trial)

exosomes from mesenchymal stem cells (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blister (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Viral (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 3